From USFDA
Zydus Cadila has received the final approval from the USFDA to market Entecavir Tablets in the strengths of 0.5 mg and 1 mg. The drug is used in the treatment of Hepatitis B Virus Infection and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sale for Entecavir tablets is $ 166.3 million.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
